SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,106.79 |
| Enterprise Value ($M) | 1,558.45 |
| Book Value ($M) | 668.54 |
| Book Value / Share | 10.68 |
| Price / Book | 1.66 |
| NCAV ($M) | -162.45 |
| NCAV / Share | -2.59 |
| Price / NCAV | -6.81 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | 0.05 |
| Return on Assets (ROA) | 0.05 |
| Return on Equity (ROE) | 0.10 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 11.48 |
| Current Ratio | 12.56 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 400.62 |
| Assets | 1,231.61 |
| Liabilities | 563.07 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Franklin Resources Inc | 10.20 | 0.00 | |
| 13D/A | Tang Capital Partners Lp | 100.00 | -100.00 | |
| 13G/A | Putnam Investments Llc | 9.80 | 17.66 | |
| 13G/A | Renaissance Technologies Llc | 6.47 | -2.01 | |
| 13G/A | Frazier Life Sciences Public Fund, L.P. | 0.00 | -100.00 | |
| 13G/A | Vanguard Group Inc | 10.47 | -5.09 | |
| 13G | Dimensional Fund Advisors Lp | 7.00 | ||
| 13G/A | BlackRock, Inc. | 16.10 | -2.48 | |
| 13D/A | Orbimed Advisors Llc | 40.10 | 0.00 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A (Amendment No. 2) | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 114,551 | 709,694 | 16.14 | |
| 151,656 | 670,089 | 22.63 | |
| 154,147 | 467,847 | 32.95 | |
| 55,432 | 336,380 | 16.48 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| INDV – Indivior PLC | INNV – InnovAge Holding Corp. |
| INSM – Insmed Incorporated | INZY – Inozyme Pharma, Inc. |
| IOBT – IO Biotech, Inc. |